SPARC, a phase-I trial of pre ‐operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer

Surgical resection aims to achieve long-term disease control in pancreatic cancer, but even when adjuvant chemotherapy is prescribed, 50% of patients will suffer local recurrence [1] and improvement in multi ‐modal therapy is therefore required. For patients with positive surgical resection margins, survival outcomes are similar to those for patients who present with unresectable disease [2–4], and despite centralisation of surgery and improved pre-operative investigations, positive margins are repo rted in around 35-60% of UK patients [5,6].

Source: Radiotherapy and Oncology - November 17, 2020 Category: Radiology Authors: Daniel L.P. Holyoake, Maxwell Robinson, Michael Silva, Derek Grose, David McIntosh, David Sebag-Montefiore, Ganesh Radhakrishna, Somnath Mukherjee, Maria A. Hawkins Tags: Original Article Source Type: research